Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.

Harris M, Rhodes T.

Harm Reduct J. 2013 May 7;10:7. doi: 10.1186/1477-7517-10-7. Review.

2.

Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study.

Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP.

Harm Reduct J. 2014 Jan 14;11:1. doi: 10.1186/1477-7517-11-1.

3.

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH.

World J Gastroenterol. 2013 Nov 28;19(44):7846-51. doi: 10.3748/wjg.v19.i44.7846. Review.

4.

Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Arain A, Robaeys G.

World J Gastroenterol. 2014 Sep 28;20(36):12722-33. doi: 10.3748/wjg.v20.i36.12722. Review.

5.

Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.

Alavi M, Grebely J, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ; Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) Study Group.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S62-9. doi: 10.1093/cid/cit305.

6.

Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.

Bruggmann P, Grebely J.

Int J Drug Policy. 2015 Feb;26 Suppl 1:S22-6. doi: 10.1016/j.drugpo.2014.08.014. Epub 2014 Aug 30.

7.

Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.

Treloar C, Newland J, Rance J, Hopwood M.

J Viral Hepat. 2010 Dec;17(12):839-44. doi: 10.1111/j.1365-2893.2009.01250.x.

PMID:
20070504
8.

Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.

Mravčík V, Strada L, Stolfa J, Bencko V, Groshkova T, Reimer J, Schulte B.

Patient Prefer Adherence. 2013 Oct 17;7:1067-75. doi: 10.2147/PPA.S49113. Review.

9.

Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research.

Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C, McVeigh J, Bellis MA.

Int J Drug Policy. 2014 Mar;25(2):204-11. doi: 10.1016/j.drugpo.2013.11.004. Epub 2013 Nov 21. Review.

PMID:
24332457
10.

Recommendations for the management of hepatitis C virus infection among people who inject drugs.

Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S129-37. doi: 10.1093/cid/cit302.

11.

Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

Bruggmann P, Litwin AH.

Clin Infect Dis. 2013 Aug;57 Suppl 2:S56-61. doi: 10.1093/cid/cit271. Review.

12.

Positive health beliefs and behaviours in the midst of difficult lives: women who inject drugs.

Olsen A, Banwell C, Dance P, Maher L.

Int J Drug Policy. 2012 Jul;23(4):312-8. doi: 10.1016/j.drugpo.2012.01.003. Epub 2012 Jun 19.

PMID:
22721571
13.

Case-finding for hepatitis C in primary care: a mixed-methods service evaluation.

Datta S, Horwood J, Hickman M, Sharp D.

Br J Gen Pract. 2014 Feb;64(619):e67-74. doi: 10.3399/bjgp14X677112.

14.

From principles to practice: Description of a novel equity-based HCV primary care treatment model for PWID.

Milne R, Price M, Wallace B, Drost A, Haigh-Gidora I, Nezil FA, Fraser C.

Int J Drug Policy. 2015 Oct;26(10):1020-7. doi: 10.1016/j.drugpo.2015.07.009. Epub 2015 Jul 21.

PMID:
26277611
15.

Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.

MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, Taylor A, Roy K, Aspinall E, Goldberg D, Rhodes T, Hedrich D, Salminen M, Hickman M, Hutchinson SJ.

Int J Drug Policy. 2014 Jan;25(1):34-52. doi: 10.1016/j.drugpo.2013.07.001. Epub 2013 Aug 21. Review.

PMID:
23973009
16.

A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region.

Lazarus JV, Sperle I, Maticic M, Wiessing L.

BMC Infect Dis. 2014;14 Suppl 6:S16. doi: 10.1186/1471-2334-14-S6-S16. Epub 2014 Sep 19. Review.

17.

The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?

Harris M, Albers E, Swan T.

Int J Drug Policy. 2015 Oct;26(10):963-9. doi: 10.1016/j.drugpo.2015.05.005. Epub 2015 Jun 4.

PMID:
26143385
18.

WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs.

Walsh N, Verster A, Rodolph M, Akl EA.

Int J Drug Policy. 2014 May;25(3):363-71. doi: 10.1016/j.drugpo.2014.01.009. Epub 2014 Jan 26.

PMID:
24561223
19.

Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users.

Coupland H, Day C, Levy MT, Maher L.

Health Promot J Austr. 2009 Dec;20(3):234-40.

PMID:
19951245
20.

The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.

Rance J, Newland J, Hopwood M, Treloar C.

Soc Sci Med. 2012 Jan;74(2):245-53. doi: 10.1016/j.socscimed.2011.10.003. Epub 2011 Nov 20.

PMID:
22133583
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk